Volume 53, Issue 5, Pages (November 2010)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
H. Mansell, L.J. Worobetz, T. Sylwestrowicz, A.S. Shoker 
Volume 62, Issue 6, Pages (June 2015)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 41, Issue 6, Pages (December 2004)
Inflammasomes in liver diseases
Volume 58, Issue 1, Pages (January 2013)
MELD: the holy grail of organ allocation?
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Volume 53, Issue 6, Pages (December 2010)
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Volume 53, Issue 6, Pages (December 2010)
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Volume 140, Issue 7, Pages e1 (June 2011)
Dynamics of serum procalcitonin in patients after major neurosurgery
B. Beović, S. Kreft, J. Osredkar, D. Keše, B. Bonač-Tuma 
Living donor liver transplantation: is the hype over?
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Mauro Bernardi, Stefano Gitto, Maurizio Biselli  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs , ABCB11 rs , and RNF7 rs Genotypes in Chronic.
Regional ventilation in cystic fibrosis measured by electrical impedance tomography  Zhanqi Zhao, Rainald Fischer, Inéz Frerichs, Ullrich Müller-Lisse,
Volume 57, Issue 2, Pages (August 2012)
Control of iron metabolism – Lessons from neonatal hemochromatosis
Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease
Volume 62, Issue 3, Pages (March 2015)
Volume 44, Issue 1, Pages (January 2006)
Epstein–Barr virus BZLF1 gene polymorphisms: malignancy related or geographically distributed variants?  M.A. Lorenzetti, M. Gantuz, J. Altcheh, E. De.
Volume 44, Issue 6, Pages (June 2006)
EASL Clinical Practice Guidelines: Wilson’s disease
Pierre Nahon, Jessica Zucman-Rossi  Journal of Hepatology 
Sex and Acquired Cofactors Determine Phenotypes of Ferroportin Disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Julie Parkes, Indra Neil Guha, Paul Roderick, William Rosenberg 
Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels  Elena Rodríguez-Iñigo, Juan Manuel López-Alcorocho,
Volume 65, Issue 2, Pages (August 2016)
Volume 57, Issue 5, Pages (November 2012)
Volume 120, Issue 6, Pages (May 2001)
Volume 71, Issue 11, Pages (June 2007)
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations  Ian E. Bosdet, T. Roderick.
Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C  Keyur Patel, David R. Nelson, Don C.
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 64, Issue 6, Pages (June 2016)
Volume 67, Issue 5, Pages (November 2017)
Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains  P. Trémeaux, A. Caporossi,
Volume 66, Issue 1, Pages (January 2017)
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Systematic reviews and meta-analyses of diagnostic test accuracy
Chronic hepatitis B in children and adolescents
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Evaluation of diagnostic tests
Volume 60, Issue 1, Pages (January 2014)
Liver transplantation in children
Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis  Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen 
Pathogenesis of cholestatic hepatitis C
Volume 44, Issue 1, Pages (January 2006)
Editorial II: Solid as a ROC
Genetics of hepatocellular carcinoma: The next generation
Volume 70, Issue 5, Pages (May 2019)
MELD: the holy grail of organ allocation?
Volume 53, Issue 4, Pages (October 2010)
Presentation transcript:

Volume 53, Issue 5, Pages 941-949 (November 2010) Ferroportin disease: A systematic meta-analysis of clinical and molecular findings  Roman Mayr, Andreas R. Janecke, Melanie Schranz, William J.H. Griffiths, Wolfgang Vogel, Antonello Pietrangelo, Heinz Zoller  Journal of Hepatology  Volume 53, Issue 5, Pages 941-949 (November 2010) DOI: 10.1016/j.jhep.2010.05.016 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Genotype to phenotype correlation of ferroportin disease: patients with ferroportin disease identified from the systematic meta-analysis were grouped according to the SLC40A1 mutation. Box-Whisker blots of (A) serum ferritin, and (B) transferrin saturation in mutations reported in more than 5 patients are shown. Boxes represent 25th and 75th percentile, Whiskers range and horizontal lines represent the median. Outliers are shown as circles. Grey, dark blue, and light blue boxes indicate that all patients reported with the respective mutation were classified as classical, non-classical, or variable biochemical phenotype, respectively, i.e. all patients had low or normal transferrin saturation (grey), increased transferrin saturation (dark blue), or different patients with the same mutation had variable transferrin saturation (light blue). Any outliers are marked with a circle and extreme cases with an asteriks. Journal of Hepatology 2010 53, 941-949DOI: (10.1016/j.jhep.2010.05.016) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Phylogenetic alignment of ferroportin protein sequences of various species: Disease-associated ferroportin gene mutations are highlighted in light blue. Single nucleotide polymorphisms are shown in dark blue. Journal of Hepatology 2010 53, 941-949DOI: (10.1016/j.jhep.2010.05.016) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Diagnostic performance analysis (ROC curve) of PolyPhen and SIFT scores for the prediction of the functional consequence of ferroportin gene variants. Genetic variants of SLC40A1 reported as polymorphisms were used as true negatives and genetic variants of SLC40A1 identified in patients with ferroportin disease were used as true positives. ROC curves are shown with the sensitivity plotted along the abscissa, and 1 – specificity plotted along the ordinate. Journal of Hepatology 2010 53, 941-949DOI: (10.1016/j.jhep.2010.05.016) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions